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Beyond open data: realising the health benefits of
sharing data
Accessible data are not enough. We need to invest in systems that make the information useful,
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As little as a decade ago, many researchers working in global
health recoiled at the idea that they should openly share
individual patient data with one another. Now, data sharing is
being herded into the mainstream by pioneering researchers,
with added pressure from funders, medicine regulatory
authorities, public health agencies, and medical journals.1-6 But
even those researchers most willing to share data are given little
guidance on how that should happen, and the practice is still
unusual, especially in low and middle income countries.
Concerns continue to be raised that data sharing will lead to
data being analysed by rich institutions in industrialised
countries while researchers in poorer countries with the highest
burdens of infectious disease will lose control of their data and
get little in return. Some fear that data sharing might harm
patients and communities by breaching confidentiality, that the
infrastructure is not up to it, and there is nowhere safe to put
shared data.7
Our group includes researchers working for academic and
humanitarian organisations, as well as public, charitable, and
industry funders of data sharing efforts. Althoughwe have raised
concerns in the past,8-13 we are now involved in sharing
information collected in low and middle income settings,
including demographic surveillance data and the records of
individual patients in clinical trials. We examine the extent to
which the fears about data sharing have been realised in our
work and what is needed to get the most value out of shared
data.
Getting more health out of the same data
Data sharing is often asserted to be good for health and to
generate new information that can save lives.14 We found many
examples where this was demonstrably true, with analyses of
data pooled from different studies in different locations
providing new information relevant to appropriate dosing,
improved treatment of subgroups, and the development of new
treatments.15-18
Box 1 lists some of the better known data sharing models. One
example is a meta-analysis of individual patient data from a
large and diverse population of patients shared through the
WorldWide Antimalarial Resistance Network (WWARN). This
provided the power to determine the efficacy of antimalarial
drug dihydroartemisinin-piperaquine across a wide range of age
groups and settings.19 The meta-analysis revealed that treatment
failure associated with a lower dose of piperaquine was
particularly dangerous in young children, suggesting potential
for further dose optimisation. The results contributed to a
revision of the World Health Organization’s guidelines for
treating malaria.20
We also identified areas where the failure to share data has
disrupted efforts to respond rapidly to outbreaks or foreclosed
more detailed evaluation of interventions that may be
harmful.21 22 In these cases, not sharing data has been bad for
science and almost certainly bad for health. In the 2014 Ebola
outbreak in west Africa some researchers made genomic data
immediately available for further study, confirming that the
virus had spread from Guinea to Sierra Leone, that it was
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Box 1: Examples of data sharing platforms
INDEPTH Network—An investigator led network of 49 health and demographic surveillance sites in 20 low and middle income countries.
Core data from each site are standardised and made available to other researchers through a web based platform. Based in Accra, Ghana
(http://www.indepth-network.org/)
WorldWide Antimalarial Resistance Network—An investigator led network of 260 collaborators, most performing clinical trials related to
malaria drug efficacy and resistance in endemic countries. Data are standardised by platform staff and shared in order to answer specific
research questions, with the approval of data contributors. Based at Oxford University, UK. (http://www.wwarn.org/)
Clinical Study Data Request—An online repository of clinical trial data contributed to by 13 major drug companies. Data are not standardised;
individual study data are made available to researchers on request, after research proposals are approved by an independent data access
panel (https://clinicalstudydatarequest.com/)
West Africa Network of Excellence for TB, AIDS, and Malaria—A regional collaboration between research institutions that aims to build
skills and structures to generate shareable clinical research data through use of common protocols for research, analysis and datamanagement.
Coordinated from Dakar, Senegal (http://orlysoft.com/sites/wanetam/)
Yale University Open Data Access—A platform for access to patient level data from clinical trials, currently mostly industry sponsored.
Platform staff provide some standardisation and curation services. Data are made available to researchers on request, after research
proposals are approved by an independent data access panel. Based at Yale University, USA (http://yoda.yale.edu/)
Figshare—A repository that allows individual researchers to upload datasets in any format at no charge. Datasets are assigned a citable
doi. Though minimal metadata must be supplied, data are not standardised or quality assured. Data published on Figshare are reuseable
by anyone with internet access under Creative Commons CC0 licence. Based in London, UK (https://figshare.com/)
Infectious Diseases Data Observatory—A collection of data sharing platforms focused on emerging and infectious diseases. Centralised
data curation and standardisation produce pooled databases from clinical trials, surveillance and/or treatment records. Data are accessible
to requestors through an independent data access committee. The expanding portfolio of disease platforms currently includes Ebola, malaria,
and visceral leishmaniasis. Based at the University of Oxford, UK (https://www.iddo.org/)
sustained by human-to-human transmission, and that it was
mutating rapidly in certain areas. However, the researchers
subsequently reported that “What followed was three months
of stasis, during which no new virus sequence information was
made public [even though] thousands of samples were
transferred to researchers' freezers across the world.”23 They
called for greater data sharing through collaborative networks.
Our investigations suggest that in lower income settings such
networks account for most of the examples in which new
knowledge was derived from shared data. These networks are
characterised by substantial investment in the sometimes
difficult work of building trust and relationships between
investigators and in developing institutional capacity, as well
as in managing and standardising data.24
In discussing data sharing policies, we propose classifying
shared data as accessible, useable, or useful, as shown in table
1⇓.
Developing and maintaining curated platforms for “useful”
sharing of data tends to be expensive. Data from different
sources, often collected in different formats using different
protocols and endpoints, must be quality controlled and
standardised so that analysis can be performed across studies.25
The upfront costs of developing community standards and
networks of collaboration can be high. However, once these
investments have been made, the time and effort required by
potential users is relatively low, and the potential for data to be
reused in ways that benefit public health is high, making the
investments cost effective.
Currently, most efforts to standardise clinical data in this way
occur within consortiums or networks of people with similar
interests who work together to formulate new questions and to
answer them in contextually appropriate ways. Data shared in
these networks may thus not always meet the transparency
criteria increasingly required by journals to allow for
independent reanalysis of individual datasets.
Replicate analyses have been done with useable datasets, and
their open availability promotes transparency in research. Drug
companies have recently taken a lead in making data from
individual clinical trials available in increasingly useable
forms.26 27The first evaluation of prominent platforms for sharing
clinical trial data found that, although individual patient data
from more than 3000 trials had been made available to
investigators over the past two years, only 15.5% of the trial
datasets had ever been requested.28 Most proposals focused on
subgroups or predictors of response not prespecified in the
original analysis rather than validation of study results, and only
one of the proposals examined had led to a published pooled
analysis and contributed to public scientific discourse.29 This is
probably because the hard work of harmonising datasets lies
with the secondary analyst, who may be reluctant to invest
heavily in data management because secondary analysis is
widely perceived to be difficult to publish. These repositories
are only recently established, however, and data requests are
on the rise.30
Power of technology
Datasets and even data repositories have multiplied so rapidly
and chaotically that one of our group likened them to an asteroid
field. Better technology and metadata standards—especially
common search portals, improved discoverability, and tools for
reliable anonymisation and standardisation of heterogeneous
data—could begin to reshape the asteroid field into an organised
solar system.
Developing that solar system and keeping the planets in orbit
will require substantial long term investment. In recent years,
the pharmaceutical industry has expanded efforts in data
transparency through platforms such as
clinicalstudydatarequest.com and has begun the process of
transforming useable data into something more useful through
data standardisation and curation in fields such as oncology. In
some cases it is outsourcing this work to academic
institutions—for example, the YODA platform held at Yale.
There is scope to expand these public-private partnerships using
fees from well resourced diseases to subsidise curation of data
for conditions with less commercial appeal.
Realistically, however, grants from development institutions
are likely to remain a key source of funding for data platforms
for neglected diseases. Currently, few such institutions provide
long term funding for data infrastructure and curation. In
addition, the groups best connected to those funding sources
tend to be academic, and academic researchers may not be best
placed to design or build the data solar system. Initiatives such
as the Clinical Data Interchange Standards Consortium are
crowdsourcing metadata standards from scientists, but we need
to draw on data management expertise from the vast data
industry outside academia to develop data sharing platforms
most efficiently, not least in order to reduce unnecessary
reinvention and duplication.
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Do no harm
Concerns that patient confidentiality and consent may be
breached are often cited by researchers as a reason for not
sharing data.13 Several of us have been sharing data for a decade
or more, including around illicit behaviours and stigmatised
diseases.31 Between us we could find few examples of
harm—certainly far fewer than examples of benefits—partly
because we have worked hard to develop strong governance
structures. We have also consulted with patients and
communities about sharing the information they provide to us,
because we believe that efforts to expand data sharing can
succeed only with broad social support.32 While governance
structures for secondary analysis should be simplified so that
they are proportionate to the often more limited risks of data
reuse, they must remain robust. These governance protocols
should be shared more widely as we gain experience in how to
maximise useful sharing while minimising risks. Collaboration
around governance also reduces the hurdles to contributing data
to repositories for pooled analyses.
Equity in research: the threat of data
parasites
A common generalisation in discussions of data sharing is that
it undermines the career prospects for researchers, especially
in low andmiddle income countries, exposing them to “research
parasites” who will ingest their data into far-off computers and
beget papers for high impact journals.33 34 We could find no
evidence for this. It is difficult to pick poorly documented data
out of scattered repositories and make coherent, publishable
sense of it. When well documented data are shared usefully in
professional networks, our experience is that sharing has
increased our work's visibility and expanded our
collaborations.13 35 Investigator led networks in which secondary
users work collaboratively with the researchers collecting the
data to define and answer questions are an important start in
moving towards a “fair trade” culture in health research, though
it is still only a start. In journal publications of secondary
analyses, first and last authors are still most often fromwealthier
countries.
Conducting clinical trials and other health research in low and
middle income countries is time consuming, challenging, and
often financially insecure. It leaves investigators with little time
to build up, let alone exercise the skills needed for large scale
secondary analysis of pooled datasets.8 Data sharing
collaborations have the potential to introduce greater equity in
global health research, but that will require long term
investments in both skills and career pathways for researchers
from countries with high disease burden. Changing the incentive
system to reward the publication of quality assured datasets
with standardised metadata in the same way that we reward the
publication of research papers in high impact journals would
go a long way to damping down the panic about data parasites.
Towards a data sharing solar system
In our experience sharing data from demographic surveillance
and health research, including clinical trial data at the individual
patient level, can lead to advances in knowledge that wouldn't
have been possible without bringing those data together. To that
extent, data sharing is good for health. But knowledge improves
health only if it leads to changes in policy and practice; one of
the most important determinants of the translation of research
results into health policy in low and middle income settings is
collaboration between local researchers and policy makers in
shaping research questions and interpreting results.36
Most examples of policy change based on analysis of shared
data in low and middle income settings involve compendiums
of datasets that are quality controlled, standardised, and
otherwise highly curated.15-20 In general, the analyses are
performed in collaborations between global disease experts and
local researchers who know their contexts well and who help
formulate questions and answer them. These researchers can
also act as a bridge to national policy makers, ultimately
delivering changes that benefit the populations fromwhich data
were collected.
This sort of sharing requires far more effort than simply
uploading a dataset to an online repository. Useful scientific
collaborations are expensive to develop and require a shift in
attitudes, incentives, and investment patterns. A degree of
technical and economic efficiency may have to be sacrificed in
the interests of fostering collaboration and equity—for example,
by investing in building skills in high disease burden countries
rather than simply using skills already available in universities
in industrialised countries. The peer reviewed research results
paper must lose its supremacy as the major metric of scientific
productivity; and funders must commit to long term investments
in both technical and human infrastructure if they want to
promote data sharing that is useful, used, and likely to change
policies for the greater benefit of patients.
This cannot happen for all diseases or all types of data at
once—it is just too expensive. The alternative is not, however,
to downgrade to a useable (but not used) or accessible (and not
useable) model of data sharing. Rather, we must think in fresh
ways about how existing structures can be made more useful to
maximise health gains. We need to figure out which platforms
and technological structures can be shared across diseases and
which diseases would most benefit from the sort of pooled
analysis that has already proved useful. Obvious candidates
include neglected tropical diseases and other infectious diseases
in poor regions with only sparse data and small sample sizes;
emerging infections about which little is known; and diseases
such as tuberculosis and malaria that face changes in disease
burden and spreading drug resistance. The value of investing
in a platform is also likely to be affected by many other factors,
including the potential for data standardisation, the institutional
politics in which the disease is embedded, and the degree to
which research is financed by public or charitable bodies.
We need to stop thinking of data sharing as an afterword to the
scientific enterprise: it is relevant to every stage of the research
cycle. Depositing decontextualised results into a growing
asteroid field may tick a transparency box, but it is otherwise
wasteful. To be useful in the low and middle income settings
which shoulder high burdens of disease and a legacy of
under-investment in research infrastructure, data sharing must
be treated as an integral part of the larger scientific solar system.
We favour sharing data, certainly, but only as one part of a
research collaboration that also fairly shares models of
governance and the tools, technology, and analytical skills that
turn shared data into better health.
Contributors and sources: The authors of this paper all participated in
a workshop held under the auspices of the Geneva Health Forum in
April 2016, supported by the Wellcome Trust and the Bill and Melinda
Gates Foundation. All the authors were invited to participate in the
discussions because they have shared health research data, funded or
supported data sharing, or advocate it through their professional position.
EP wrote the first draft and is the guarantor.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;355:i5295 doi: 10.1136/bmj.i5295 (Published 10 October 2016) Page 3 of 5
ANALYSIS
Key messages
Simple accessibility of data is enough to promote research transparency, but public health gains require more complex models
Meaningful and equitable collaboration with local researchers and policy makers in low and middle income countries is needed to ensure
the right research questions get asked and research results are used
Useful data sharing requires long term investment in infrastructure, networks, and scientific careers, including in the data sciences
It is not enough to share data: we need to share governance structures, scientific questions and ideas, and interpretation
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Table
Table 1| Benefits and costs of different levels of data sharing
Upfront curation costsPotential health benefitResearch becomes transparent
CheapUncertainYesAccessible—online repository
ModeratePossible with extensive user effortYesUseable—repository with discoverable, well documentedmetadata
ExpensiveGreatSometimesUseful—data are curated, standardised, and comparable across
time and place
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